Andrew L. Himelstein, MD
Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, those who used zoledronic acid every 12 weeks, compared with the standard dosing interval of every 4 weeks, did not experience an increased risk of skeletal-related events (SREs) over 2 years. These findings come from a recently published study in the Journal of the American Medical Association
He added that, “Denosumab appears to be slightly more effective than zoledronic acid. It's also a lot more expensive. At the time, dosing requires monthly visits to the doctor with injections under the skin. At some point, future research could look at less frequent zoledronic acid directly compared to denosumab.”
Himelstein AL, Foster JC, Khatcheressian L, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases. JAMA. 2017;317(1):48-58.
... to read the full story